FGF23与FGFR4促进慢性肾脏病心脏代谢重构
该研究在腺嘌呤饮食诱导的慢性肾脏病(CKD)野生型小鼠中发现,线粒体结构改变和心脏代谢功能障碍先于左心室肥厚(LVH)出现。体外实验显示FGF23通过激活FGFR4导致线粒体病理和生物能量应激。全局及心脏特异性敲除FGFR4可预防CKD小鼠的心脏代谢改变和线粒体异常。
要点
- CKD小鼠心脏代谢重构和线粒体功能障碍早于LVH发生
- FGF23通过激活FGFR4介导心肌细胞线粒体损伤和糖酵解增加
- 敲除FGFR4可预防CKD小鼠心脏代谢及线粒体改变
核心结论
- 代谢重构和线粒体功能障碍是CKD早期心脏并发症,先于心脏结构重构。
- FGF23通过激活FGFR4引起线粒体功能障碍,早期药物抑制FGFR4可能预防CKD患者LVH和心力衰竭。
研究设计与样本
- 野生型小鼠经腺嘌呤饮食诱导CKD模型。
- 体外使用生物工程心肌束和新生大鼠心室肌细胞。
- 通过全局和心脏特异性敲除FGFR4进行干预验证。
主要发现
- CKD小鼠出现线粒体结构形态改变和心脏代谢功能障碍,且先于LVH发展。
- 体外FGF23介导的FGFR4激活导致线粒体病理,表现为生物能量应激增加和糖酵解增加,先于细胞肥大。
- 全局和心脏特异性敲除FGFR4可预防CKD小鼠的心脏代谢改变及相关线粒体异常。
临床怎么用
- 早期识别CKD患者心脏代谢和线粒体功能障碍可能有助于预防LVH。
- FGFR4可能作为早期药物干预靶点,以预防CKD患者LVH和心力衰竭。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) is a global health epidemic that greatly increases mortality due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiac injury in CKD. High serum levels of fibroblast growth factor (FGF) 23 in patients with CKD may contribute mechanistically to the pathogenesis of LVH by activating FGF receptor (FGFR) 4 signaling in cardiac myocytes. Mitochondrial dysfunction and cardiac metabolic remodeling are early features of cardiac injury that predate development of hypertrophy, but these mechanisms have been insufficiently studied in models of CKD. We found in wild-type mice with CKD induced by adenine diet, that morphological changes occurred in mitochondrial structure and cardiac mitochondrial and that metabolic dysfunction preceded the development of LVH. In bioengineered cardio-bundles and neonatal rat ventricular myocytes grown in vitro, FGF23-mediated activation of FGFR4 caused mitochondrial pathology, characterized by increased bioenergetic stress and increased glycolysis that preceded the development of cellular hypertrophy. The cardiac metabolic changes and associated mitochondrial alterations in mice with CKD were prevented by global and cardiac-specific deletion of FGFR4. Our findings indicate that metabolic remodeling and mitochondrial dysfunction are early cardiac complications of CKD that precede structural remodeling of the heart. Mechanistically, FGF23-mediated activation of FGFR4 causes mitochondrial dysfunction, suggesting that early pharmacologic inhibition of FGFR4 might serve as novel therapeutic intervention to prevent development of LVH and heart failure in patients with CKD.
引用
- Fuchs MAA, Burke EJ, Latic N, et al. Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease. Kidney Int. 2025. PMID: 39923962. doi:10.1016/j.kint.2025.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。